Open Access
Recent Development of Prodrugs of Gemcitabine
Тип публикации: Journal Article
Дата публикации: 2022-03-05
PubMed ID:
35328020
Genetics
Genetics (clinical)
Краткое описание
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Different drug delivery strategies have also been employed, seeking to transform gemcitabine into a targeted medicine. This review will provide an overview of the recent developments in gemcitabine prodrugs and their effectiveness in treating cancerous tumors.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
3
|
|
|
European Journal of Medicinal Chemistry
3 публикации, 4%
|
|
|
Molecules
3 публикации, 4%
|
|
|
Pharmaceutics
2 публикации, 2.67%
|
|
|
Frontiers in Oncology
2 публикации, 2.67%
|
|
|
Biochemical and Biophysical Research Communications
2 публикации, 2.67%
|
|
|
Frontiers in Pharmacology
2 публикации, 2.67%
|
|
|
Russian Journal of Bioorganic Chemistry
2 публикации, 2.67%
|
|
|
Bioorganic Chemistry
2 публикации, 2.67%
|
|
|
Journal of Medicinal Chemistry
1 публикация, 1.33%
|
|
|
Antibiotics
1 публикация, 1.33%
|
|
|
Acta Biomaterialia
1 публикация, 1.33%
|
|
|
European Journal of Pharmacology
1 публикация, 1.33%
|
|
|
Biomedicines
1 публикация, 1.33%
|
|
|
Organic Chemistry Frontiers
1 публикация, 1.33%
|
|
|
Advanced Materials
1 публикация, 1.33%
|
|
|
Frontiers in Endocrinology
1 публикация, 1.33%
|
|
|
Discover Nano
1 публикация, 1.33%
|
|
|
MedComm
1 публикация, 1.33%
|
|
|
Nutrients
1 публикация, 1.33%
|
|
|
International Journal of Quantum Chemistry
1 публикация, 1.33%
|
|
|
Cells
1 публикация, 1.33%
|
|
|
World Journal of Gastrointestinal Oncology
1 публикация, 1.33%
|
|
|
Cancer Treatment Reviews
1 публикация, 1.33%
|
|
|
Materials Advances
1 публикация, 1.33%
|
|
|
Genome Instability & Disease
1 публикация, 1.33%
|
|
|
Biochemical Pharmacology
1 публикация, 1.33%
|
|
|
Frontiers in Immunology
1 публикация, 1.33%
|
|
|
Journal of Colloid and Interface Science
1 публикация, 1.33%
|
|
|
Oncogene
1 публикация, 1.33%
|
|
|
1
2
3
|
Издатели
|
5
10
15
20
|
|
|
Elsevier
20 публикаций, 26.67%
|
|
|
MDPI
13 публикаций, 17.33%
|
|
|
Springer Nature
11 публикаций, 14.67%
|
|
|
Wiley
8 публикаций, 10.67%
|
|
|
Frontiers Media S.A.
6 публикаций, 8%
|
|
|
American Chemical Society (ACS)
3 публикации, 4%
|
|
|
Royal Society of Chemistry (RSC)
3 публикации, 4%
|
|
|
Pleiades Publishing
2 публикации, 2.67%
|
|
|
Cold Spring Harbor Laboratory
1 публикация, 1.33%
|
|
|
Baishideng Publishing Group
1 публикация, 1.33%
|
|
|
Oxford University Press
1 публикация, 1.33%
|
|
|
SAGE
1 публикация, 1.33%
|
|
|
AME Publishing Company
1 публикация, 1.33%
|
|
|
Taylor & Francis
1 публикация, 1.33%
|
|
|
Spandidos Publications
1 публикация, 1.33%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 1.33%
|
|
|
5
10
15
20
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
75
Всего цитирований:
75
Цитирований c 2025:
36
(48%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Pandit B., Royzen M. Recent Development of Prodrugs of Gemcitabine // Genes. 2022. Vol. 13. No. 3. p. 466.
ГОСТ со всеми авторами (до 50)
Скопировать
Pandit B., Royzen M. Recent Development of Prodrugs of Gemcitabine // Genes. 2022. Vol. 13. No. 3. p. 466.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.3390/genes13030466
UR - https://doi.org/10.3390/genes13030466
TI - Recent Development of Prodrugs of Gemcitabine
T2 - Genes
AU - Pandit, Bhoomika
AU - Royzen, Maksim
PY - 2022
DA - 2022/03/05
PB - MDPI
SP - 466
IS - 3
VL - 13
PMID - 35328020
SN - 2073-4425
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2022_Pandit,
author = {Bhoomika Pandit and Maksim Royzen},
title = {Recent Development of Prodrugs of Gemcitabine},
journal = {Genes},
year = {2022},
volume = {13},
publisher = {MDPI},
month = {mar},
url = {https://doi.org/10.3390/genes13030466},
number = {3},
pages = {466},
doi = {10.3390/genes13030466}
}
Цитировать
MLA
Скопировать
Pandit, Bhoomika, and Maksim Royzen. “Recent Development of Prodrugs of Gemcitabine.” Genes, vol. 13, no. 3, Mar. 2022, p. 466. https://doi.org/10.3390/genes13030466.